Clinical trial NCT01967043: A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies
Official title: A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Solid Tumor
Lead sponsor: Athenex, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Atlantic Research Group
First posted: 2013-10-22
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a standard "3+3" Phase 1b study to determine the MTD of Oraxol (paclitaxel + HM30181 Methanesulfonate monohydrate) in subjects with advanced malignancies that may be metastatic or unresectable with measurable malignant lesion(s) per RECIST Version 1.1 criteria.


Eligibility criteria: Inclusion Criteria:

1. Signed written informed consent
2. ≥ 18 years of age
3. Histologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.
4. Measurable disease as per RECIST Version 1.1 criteria.
5. Adequate bone marrow reserve as demonstrated by

   * Absolute neutrophil count (ANC) ≥1.5 x 10⁹/L
   * Platelet count ≥ 100 x 10⁹/L
   * Hemoglobin (Hgb) ≥ 9 g/L
6. Adequate liver function as demonstrated by

   * Total bilirubin of ≤ 1.5 mg/dL or ≤ 2.0 mg/dL for subjects with liver metastasis
   * Alanine aminotransferase (ALT)≤ 3 x upper limit of normal (ULN) or ≤ 5x ULN if liver metastasis is present
   * ALP ≤ 3 x ULN or ≤ 5 x ULN if bone metastasis is present
7. Adequate renal function as demonstrated by serum creatinine ≤ 1.5 x ULN, or 24-hr urine creatinine clearance calculation \>60 mL/min
8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
9. Life expectancy of at least 3 months
10. Subjects who are not currently taking prohibited medication
11. Women must be postmenopausal (\> 12 months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or must be using effective contraception

Exclusion Criteria:

1. Have not recovered to ≤ Grade 1 toxicity from previous anticancer treatments or previous investigational agents
2. Received investigational agents within 14 days or 5 half-lives of the first study dosing day, whichever is longer.
3. Women of childbearing potential who are pregnant or breast feeding.
4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myocardial infarction within the last 6 months, unstable angina pectoris, cardiac arrhythmia, chronic pulmonary disease requiring oxygen, known bleeding disorders, or psychiatric illness/social situations that would limit compliance with study requirements
5. Significant or uncontrolled cardiovascular disease or bleeding disorder
6. Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the investigator may interfere with oral drug absorption
7. Subjects with a known history of allergy to paclitaxel. Subjects whose allergy was due to the IV solvent (such as Cremophor®) and not paclitaxel will be eligible for this study.

Primary outcomes:
measure: To determine the maximum tolerated dose (MTD) of Oraxol in subjects with advanced malignancies
timeFrame: one year
Secondary outcomes:
measure: To determine the recommended Phase 2 dose (RP2D) of Oraxol
timeFrame: one year six months
Other outcomes:
Locations:
city: Aurora
country: United States
facility: University of Colorado Cancer Center
state: Colorado
city: Baltimore
country: United States
facility: Johns Hopkins University
state: Maryland
city: Buffalo
country: United States
facility: Roswell Park Cancer Institute
state: New York
Study officials:
affiliation: Kinex Pharmaceuticals Inc.
name: Min-Fun Rudolf Kwan, MD
role: STUDY_DIRECTOR
References: